{
    "nctId": "NCT00436410",
    "briefTitle": "Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer",
    "officialTitle": "An Evaluation of the Tissue Distribution and the Selective Tumor Trafficking of TNF-Bound Colloidal Gold (CYT-6091) Following Intravenous Administration in Subjects With Primary and Metastatic Cancer Undergoing Surgical Resection",
    "overallStatus": "COMPLETED",
    "conditions": "Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, Kidney Cancer, Liver Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Sarcoma",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "N/A",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 108,
    "primaryOutcomeMeasure": "Tumor tissue and normal tissue distribution of colloidal gold-bound tumor necrosis factor",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed primary or metastatic malignancy, including any of the following:\n\n  * Colorectal cancer\n  * Hepatocellular cancer\n  * Pancreatic exocrine cancer\n  * Pancreatic endocrine cancer\n  * Breast cancer\n  * Melanoma\n  * Sarcoma\n  * Primary adrenal tumors\n  * Renal cell carcinoma\n  * Ovarian cancer\n  * Adenocarcinoma of gastrointestinal origin\n  * Peritoneal mesothelioma\n* Clinical indication for surgical resection\n* No known brain metastases\n\n  * Previously treated brain metastases with no evidence of recurrence allowed\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Male or female\n* Menopausal status not specified\n* ECOG performance status 0-2\n* Life expectancy \u2265 5 months\n* Absolute neutrophil count \u2265 1,500/mm\u00b3\n* Platelet count \u2265 100,000/mm\u00b3\n* Creatinine \u2264 2.0 mg/dL\n* Bilirubin \u2264 2.5 mg/dL\n* ALT and AST \u2264 3 times upper limit of normal (ULN)\n* Alkaline phosphatase \u2264 3 times ULN\n* Hemoglobin \u2265 9.0 g/dL\n* Ejection fraction \u2265 45% by echocardiogram, thallium stress test, or MUGA (for patients with prior cardiovascular disease)\n* FEV_1 OR DLCO \\> 30% of predicted (for patients with prior pulmonary disease)\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No active bacterial infection\n\n  * Localized chronic infection (e.g., mild acne, tinea pedis) allowed\n* No known bleeding disorder\n* No other serious illness including, but not limited to, any of the following:\n\n  * Unstable angina\n  * Severe oxygen-dependent chronic obstructive pulmonary disease\n  * End-stage liver disease\n* No HIV positivity\n\nPRIOR CONCURRENT THERAPY:\n\n* Recovered from prior therapy, including cytotoxic drugs, radiotherapy, surgery, or other anticancer modalities\n* More than 3 weeks since prior biologic therapy or cytotoxic agents (6 weeks for nitrosoureas) and recovered\n* No concurrent treatment in a protocol for which patient is being evaluated for response\n* No other concurrent anticancer treatment",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}